{"entity":{"id":"nct06305247","kind":"trial","name":"A Study to Assess IPN01194 When Administered Alone in Adults With Advanced Solid Tumours","aka":[],"tldr":"A phase 1/2 trial of IPN01194 in melanoma, head and neck squamous cell carcinoma, pancreatic ductal adenocarcinoma and colorectal cancer, run by Ipsen, active and no longer recruiting.","summary":"A Study to Assess IPN01194 When Administered Alone in Adults With Advanced Solid Tumours is a phase 1/2 interventional study registered as NCT06305247 by Ipsen, with 36 participants enrolled, started 2024-04-03 and due to reach its primary completion in 2028-03-20. Interventions recorded: IPN01194.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06305247","url":"https://clinicaltrials.gov/study/NCT06305247"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["melanoma","head-and-neck","pancreatic","colorectal"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["ipsen"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06305247","phase":"1/2","setting":"An Open-label, Phase I/IIa First-in-human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Antitumour Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants With Advanced Solid Tumours","sponsor":"Ipsen","enrolled":36,"outcomes":[]},"route":"/trials/nct06305247/","neighbours":{"cancer":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"},{"id":"head-and-neck","kind":"cancer","name":"Head and neck squamous cell carcinoma","route":"/cancers/head-and-neck/"},{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"},{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"}],"company":[{"id":"ipsen","kind":"company","name":"Ipsen","route":"/companies/ipsen/"}]}}